Stelis Biopharma

We continue to push frontiers with plans to enter new growth markets such as Bio-pharmaceuticals. This leverages our heritage of executing complex, high-quality drug development, cGMP manufacturing and global commercialization of generics.

About STELIS Biopharmaceuticals

STELIS Biopharma Pvt. Ltd. is a fully-owned subsidiary of Strides set up in 2013 to consolidate and augment the R&D activities of Inbiopro, which was fully acquired in 2012; and in extending the value chain to manufacturing and commercialisation of the product pipeline. 

STELIS is pursuing a blended strategy of-

developing both ‘biosimilars’ and ‘novel biotherapeutics’ to a ‘Regulated’ market (US/EU) standard for global markets. Our strategy is to offer high-quality bio-pharmaceuticals at affordable prices initially in high-growth Emerging Markets whose vast patient populations offer un-paralleled opportunities for expanded access.


STELIS Projects

We are shortly moving to a 22,000 sq. ft. state-of-the art R&D facility in Bangalore dedicated to bio-pharmaceuticals. This advanced facility will house 60 scientists and will incorporate the latest in bio-process engineering and bio-analytical techniques and support process development in both microbial and mammalian expression systems.


STELIS has partnered with Malaysian Bio-XCell Sdn. Bhd., an industrial biotech technology park and ecosystem, to set up an advanced bio-therapeutic manufacturing facility using ‘next-generation’ manufacturing and bio-process technologies which will revolutionise the way bio-molecules are manufactured. The plant, which is expected to come online in mid-2015, will have capability to produce simple and complex bio-therapeutics using microbial and mammalian systems. It will also have fill-finish capability in a variety of formats.

  • Bio-pharma represents the fastest growing market in Pharma accounting for 6 out of the top 10 selling global drugs.
  • With patents on $67 Bn worth 1st generation biologics expiring by 2020, this opens up market for ‘biosimilars’, the generic version of biological medicines.
  • Market for biosimilars expected to touch $13 Bn by 2018
  • Emerging markets are a ‘hotspot’ for biologics with biosimilar penetration rates expected to be higher than in Developed markets in near to mid-term

Stelis Brochure(s)